Gore, Lia
Locatelli, Franco
Zugmaier, Gerhard
Handgretinger, Rupert
O’Brien, Maureen M.
Bader, Peter
Bhojwani, Deepa http://orcid.org/0000-0002-7559-7927
Schlegel, Paul-Gerhardt
Tuglus, Catherine A.
von Stackelberg, Arend
Article History
Received: 1 May 2018
Revised: 11 July 2018
Accepted: 18 July 2018
First Online: 22 August 2018
Conflict of interest
: L. Gore is a stockholder of Amgen, Sanofi, Celgene, Clovis Oncology and Ignyta, has received consulting and travel honoraria from Bristol Myers-Squibb, Celgene, Genentech/Roche, Amgen, Novartis, and ProEd Communications, and holds a patent for diagnostic discovery and treatment response methodology tools in the use of MR spectroscopy for leukemia. F. Locatelli has received honoraria from Amgen and Miltenyi Biotec, consulting fees from Amgen, research funding from Neovii Biotech, and travel support from Medac. G. Zugmaier is an employee and stockholder of Amgen, and holds patents with Amgen and Micromet. R. Handgretinger holds a patent with Miltenyi Biotec. M.M. O’Brien has received consulting fees from Amgen, research funding from Amgen, Seattle Genetics, Epizyme, Celgene, and BTG and travel support from Amgen, Celgene, and AROG Pharmaceuticals. P. Bader has received consulting fees from Amgen and Novartis, and research funding from Medac, Neovii Biotech, and RIEMSER; and is a patent holder with Medac. D. Bhojwani has received travel support from Amgen. C.A. Tuglus is an employee and stockholder of Amgen. A. von Stackelberg has received honoraria from Amgen, ERYTECH Pharma, Novartis, Roche, and Jazz Pharmaceuticals, consulting fees from Amgen, ERYTECH Pharma, Novartis, and Roche, and travel support from Amgen and ERYTECH Pharma, and has been a member of a speakers’ bureau for Amgen. P.-G. Schlegel declares that he has no conflict of interest.